In non-small cell lung cancer (NSCLC) circulating tumor cells (CTCs) can provide information on patient prognosis and treatment efficacy. Currently CTCs are mostly isolated in vitro from small volumes of patient blood samples. The aim of the study was to assess a medical device for in vivo isolation of CTCs directly from the blood of NSCLC patients. The device was inserted in a cubital vein through a standard cannula for thirty minutes. The interaction of target CTCs with the CellCollector was mediated by an antibody directed against the epithelial cell adhesion molecule. There were 60 applications of the wire in 48 stage I-IIIB NSCLC patients and 12 non-cancer patients. The device was well tolerated in all applications without side effects. We obtained in vivo isolation of CTCs in 32 of 34 NSCLC patients (94.1%) with a median (range) of 13 (0-300) CTCs. In the non-cancer patients, no CTCs were detected. The safety and efficacy of an in vivo CTC detection method directly from the bloodstream of patients with NSCLC has been demonstrated. This proof of concept study may have important clinical implications, as the implementation of the device into clinical practice may improve early detection, prognosis and therapy monitoring of NSCLC patients.

Download full-text PDF

Source
http://dx.doi.org/10.4149/neo_2017_618DOI Listing

Publication Analysis

Top Keywords

nsclc patients
16
circulating tumor
8
tumor cells
8
non-small cell
8
cell lung
8
lung cancer
8
patients
8
vivo isolation
8
isolation ctcs
8
patients device
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!